Guizhou Bailing Group Pharmaceutical Co., Ltd
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Guizhou Bailing Enterprise Group Pharmaceutical Co., Ltd. (hereinafter referred to as "Guizhou Bailing") is a pharmaceutical listed company engaged in the research and development, production, and sales of Miao drugs. Its registered capital is 1411.2 million yuan, total assets are 7.059 billion yuan, and there are 6124 employees. In June 2010, the company was successfully listed on the Shenzhen Stock Exchange (stock code: SZ002424). The company clearly focuses on the strategic development goal of "strengthening the company's advantageous position in the field of traditional Chinese patent medicines and simple preparations, and striving to become an enterprise with core competitive advantages in the field of Chinese patent medicine", and focuses on the implementation of "scientific and technological Miao medicine, cultural Miao medicine, and ecological Miao medicine", and is committed to building an enterprise group with a healthy whole industry chain. Guizhou Bailing has successively won honors such as "National Intellectual Property Advantage Enterprise", "National Recognized Enterprise Technology Center", "National Contract abiding and Credit Valuing Enterprise", "National Ethnic Unity and Progress Model Collective", the fourth batch of "Green Factory" by the Ministry of Industry and Information Technology, "Leading Enterprise in Agricultural Industrialization", and the first "Provincial Governor Quality Award" in Guizhou. It has been selected for many years in the list of China's Top 100 Pharmaceutical Industry and Guizhou's "Double Top 100 Enterprises". Brand influence is one of the core competitiveness of a company. After more than 20 years of development, the company has continuously increased its investment in brand construction while expanding its scale, in order to enhance the company's brand market awareness and influence. After years of development, the company has formed a strong product architecture and brand system led by the "Bailingniao" brand of cardiovascular and cerebrovascular medicine Yindan Xinnaotong Soft Capsules, cold and cough medicine Vitamin C Yinqiao Tablets, Kesuting Syrup and Capsules, Jingan Capsules, Children's Chaigui Antipyretic Granules, as well as gynecological drugs such as Kangfuling Capsules, Jingdai Ning Capsules, and other traditional Chinese medicine and Miao medicine. The company's main varieties include Yindan Xinnaotong Soft Capsules, Xiao'er Chaigui Antipyretic Granules, Qiangli Pipa Lu, Yimu Cao Gao, Huanglian Shangqing Tablets, Niuhuang Jiedu Tablets, Yiqing Granules, and 36 other varieties. 54 approval documents have been selected for the National Essential Drug Catalogue (2018 version). Among them, Yindan Xinnaotong Soft Capsules are the exclusive variety in China, while Xiao'er Chaigui Antipyretic Granules are the new selected variety and the exclusive specification in China. A total of 51 varieties of the company's products, including Yindanxinnaotong Soft Capsules, Xiao'er Chaigui Antipyretic Granules, Vitamin C Yinqiao Tablets, and Bilinqing Capsules, have been included in the "Medical Insurance Catalogue" (2020 version). In 2020, Guizhou Bailing was selected as one of the "Top 100 Chinese Medicine Industry Series Rankings" and ranked among the top 30 Chinese traditional medicine enterprises. According to data from the China Over the Counter Drug Association, the company has been selected as the 18th largest manufacturer of over-the-counter drugs in China in 2021. Its products, including Kesuding Syrup/Capsules, Jingan Capsules, Vitamin C Yinqiao Tablets, Shuangyang Houbitong Granules, and Xiao'er Chaigui antipyretic Granules, have consistently ranked at the forefront of various product categories, and the ranking continues to rise. R&D advantage companies have always attached great importance to product research and development work, viewing it as the driving force for their own development, and have established a relatively complete technological innovation system. The company has won honors such as National Recognized Enterprise Technology Center, National Innovative Enterprise, National Torch Plan Key High tech Enterprise, National Level Technology Innovation Demonstration Enterprise, National Intellectual Property Advantage Enterprise, Guizhou Province Innovative Leading Enterprise Cultivation Enterprise, Guizhou Province Intellectual Property Advantage Enterprise, etc. At the same time, it has established a National and Local Joint Engineering Research Center for Modern Miao Medicine Creation Technology, a National Postdoctoral Research Workstation Academician Workstation, Guizhou Provincial Ethnic Medicine (Traditional Chinese Medicine) Compound Formulation Engineering Technology Research Center, Guizhou Southwest Ethnic Medicine (Traditional Chinese Medicine) Oral Formulation Manufacturing Technology Industry University Research Cooperation Innovation Alliance, Modern Miao Medicine Innovation Technology Research Institute, and other research and development platforms. By combining the resources of research institutes, higher education institutions, and enterprises in the fields of "production, learning, research, and application", the company has continuously strengthened its core competitiveness in drug research and development, actively exploring new models and mechanisms for collaborative innovation between schools and enterprises, promoting independent technological innovation, promoting the transformation of scientific and technological achievements, accelerating the cultivation of high-level talents in the company, meeting the needs of talent reserves, and further consolidating and enhancing the company's core competitiveness. As of 2021, the company has 88 valid patents, 65 domestic inventions, 3 exterior designs, and 20 utility models. All 17 varieties of Miao medicine produced by the company have invention patents. The company's products, Yindanxinnaotong Soft Capsules, Kesuding Syrup/Capsules, and Xiao'er Chaigui Antipyretic Granules, have won the 17th, 19th, and 21st China Patent Excellence Awards, demonstrating the intellectual property competitiveness of the company's core products. Guizhou Bailing closely follows the "Healthy China" strategy and adheres to the corporate philosophy of "specializing in medicine and focusing on people". Focusing on the strategic goal of building a moderately prosperous society in all respects, it takes improving the health of the whole people as its own responsibility, adheres to relying on mature brands and advantageous varieties as the core, continuously strengthens the construction of research and development innovation systems and investment in research and development, in order to achieve sustainable development of the company.In the future, the company will continue to focus on the development strategy of ethnic medicine and Miao medicine, with chemical medicine and biological medicine as the two wings, and strive to build an enterprise group with a large and healthy entire industry chain. |
| Headquarter | Anshun |
| Establish Date | 3/25/1999 |
| Listed Code | 002424.SZ |
| Listed Date | 6/3/2010 |
| Chairman | Jiang Wei. |
| CEO | Niumin. |
| Website | www.gzbl.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
